3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
1
Status
Active not recruiting
4
Recruiting
3
Completed
1
Approved for marketing
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
4
Conditions
Small Cell Lung Carcinoma
4
Neuroendocrine Tumors
1
Neoplasms
1
Lung Neoplasms
1
Bites and Stings
1
Interventions
Carboplatin
15
durvalumab
14
Etoposide
14
pembrolizumab
9
atezolizumab
9
Cisplatin
9
Topotecan
8
Nivolumab
7
Specimen Handling
6
olaparib
4
berzosertib
4
Temozolomide
4
Magnetic Resonance Spectroscopy
4
AMG 757
4
tremelimumab
3
Radiotherapy
3
Radiosurgery
3
PM 01183
3
Ipilimumab
3
Docetaxel
3
Biopsy
3
niraparib
2
lenvatinib
2
cabozantinib
2
Platinum
2
Irinotecan
2
Fulvestrant
2
veliparib
1
tislelizumab
1
tazemetostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Active not recruiting
×
Small Cell Lung Carcinoma
×
AMG 757
×
Clear all
NCT06117774
2026-04-29
DeLLphi-306
Amgen
Phase 3
Active not recruiting
404 enrolled
NCT06745323
2026-03-03
DeLLphi-309
Amgen
Phase 2
Active not recruiting
252 enrolled
NCT05740566
2026-01-05
DeLLphi-304
Amgen
Phase 3
Active not recruiting
509 enrolled
11 charts
1 FDA
NCT06211036
2025-12-17
DeLLphi-305
Amgen
Phase 3
Active not recruiting
563 enrolled